Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 18/20 | 0.61 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2696236 | 0.95 | CMA1 (0.60) | CMA1HTR1DOPRK1 | |
| SCHEMBL2698407 | 0.92 | CMA1 (0.59) | CMA1HTR1DOPRK1 | |
| SCHEMBL2697953 | 0.92 | CMA1 (0.59) | CMA1HTR1DOPRK1 | |
| SCHEMBL2697949 | 0.92 | CMA1 (0.59) | CMA1HTR1DOPRK1 | |
| SCHEMBL2698118 | 0.91 | CMA1 (0.62) | CMA1HTR1DOPRK1 | |
| SCHEMBL3684559 | 0.87 | CMA1 (0.47) | CMA1 | |
| SCHEMBL1294821 | 0.87 | CMA1 (0.50) | CMA1HTR1DOPRK1 | |
| SCHEMBL1294825 | 0.87 | CMA1 (0.50) | CMA1HTR1DOPRK1 | |
| SCHEMBL1294331 | 0.85 | CMA1 (0.50) | CMA1HTR1DOPRK1 | |
| SCHEMBL1294334 | 0.85 | CMA1 (0.50) | CMA1HTR1DOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501749-B2 | Azaquinazolinediones chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| EP-2391624-B1 | AZAQUINAZOLINEDIONES USEFUL AS CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2013-01-16 | — | — | EP | disclosed |
| US-20120108597-A1 | Azaquinazolinediones Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| EP-2391624-A1 | AZAQUINAZOLINEDIONES USEFUL AS CHYMASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010088195-A1 | AZAQUINAZOLINEDIONES USEFUL AS CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108597-A1 | Azaquinazolinediones Chymase Inhibitors | CMA1, SERPINB1, CTSC | CMA1 1/4885HTR1D 3120/4885OPRK1 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.